Benchmarking of mutation diagnostics in clinical lung cancer specimens - Wikidata - awgldk - TriplyDB

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Benchmarking of mutation diagnostics in clinical lung cancer specimens

http://www.wikidata.org/entity/Q28740430

about

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence Postzygotic single-nucleotide mosaicisms in whole-genome sequences of clinically unremarkable individuals Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Next-generation sequencing for cancer diagnostics: a practical perspective.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform.Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay.Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.First-line therapy of mutated non-small cell lung cancer: an update.EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.Current and future molecular diagnostics in non-small-cell lung cancer.Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.A genomics-based classification of human lung tumors.KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device.False positives in multiplex PCR-based next-generation sequencing have unique signatures.Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.

P2860

Q26828860-A86F0DC6-B028-4872-A097-E174A444920D Q26853071-851D7351-CBF7-49DF-B069-3AAA3A717A61 Q28397138-C63A2610-BAD9-48A1-994C-5C1F03EB0D48 Q33947862-7160E0BD-0C91-417C-AB5F-F7EEEBC28CBC Q34159011-66434CE7-CAB8-40F4-9D0F-9FB2764759F4 Q34238930-CBAE6274-3485-479F-AAE6-73EA8E0C21BB Q34471813-66E7790B-3D32-4E81-A282-79BE07DA8008 Q34544677-4EE5579E-A33F-415A-A5FB-F1522DA8041A Q34567984-86D838E6-075F-4987-892F-742C67325F59 Q34622721-48F9950F-A39B-4C4D-B22E-93DD6435C54B Q34749852-DD830E09-7630-43AF-8317-E18CCE6F2C75 Q34755943-D9E00E1B-49B0-47FB-BD63-5788E798F483 Q35078128-4B3FFB57-B817-436D-BC93-34FA8C3DDEED Q35721438-D6ECA7F7-0000-4BBE-B677-CE03EC650E71 Q36354817-B7D76A2E-F4A2-4200-9CF4-04F4E474AC51 Q36545907-39C66DDD-156C-49AF-B2A3-A8E91CFB477A Q36557678-681E6CB3-0FAA-4CC0-90E8-C41269EF6E60 Q36759284-BA9DEA1E-B7EE-49A4-8829-EA876F8EBE51 Q36849673-06A46901-D150-4D03-9860-B4803F5FAC4C Q36952283-023A8BA7-BC8E-4345-A04F-77CB22B2C519 Q37028777-8A45827E-BD44-46E1-AC99-99E3238DF645 Q37116350-29819FF9-3E89-4438-B472-8DF44C5DEA96 Q37313331-9A894A32-5DF8-47E7-B190-0C9961723A57 Q37607965-D11F84C3-85B9-4FF6-B8AF-D438839F827D Q37653893-D29E588D-7EEA-414F-AA39-61387282EB48 Q38032437-5486100E-FE2C-4D88-B26B-D4650F027BB1 Q38061599-ECFB698A-9B49-47F1-9254-EEE04BCD45C1 Q38194591-A094EF84-31EE-4101-9293-6E3470245912 Q38322114-371E2B89-17CD-4252-8BDE-9134916CA398 Q38390205-F70886D9-A69C-43B5-9E5B-7E080561E9F6 Q38433965-A05D9CFF-ACE9-4E85-9098-6A5642FAD09E Q38543780-C403EDE0-285F-404B-89D4-D88C707B9225 Q38790179-33C4D09C-23D4-4A2C-B504-F374427864C7 Q39073840-D1DB520E-6FE3-43CE-885E-E3845A11FADC Q39123357-D0BED382-FDEB-42EC-9F55-BFC452417F22 Q39225749-EF10FC15-AA19-47E3-BDE6-BD8DCA3D2DE7 Q40476723-3D986DA6-C49F-4F52-A1B7-DBD2C8DE8674 Q41483948-0B1F9C69-0699-413A-BBAF-60F9088D1A1D Q42129401-3781705F-FD29-4DC4-A1D4-C0184AF03A9C Q42583248-507E3FE9-C20C-4A56-80C9-3ACF8FC3B715

P2860

Benchmarking of mutation diagnostics in clinical lung cancer specimens

http://www.wikidata.org/entity/Q28740430

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@ast

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@en

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@nl

type

label

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@ast

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@en

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@nl

prefLabel

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@ast

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@en

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@nl

P1433

Q28740430-25B70E12-9A10-41A0-8103-EA8B95C4920D

P1476

Q28740430-24C7ACCC-8742-4B0B-A281-72975C92D16F

P2093

Q28740430-2CFDF097-4148-4736-AC1F-F2C04E00A233

Q28740430-2E8199D3-4B30-4988-8CE3-713FC3A04E1F

Q28740430-30924F52-BBFE-44A1-9CB5-56A7134D7F6F

Q28740430-551B0296-8231-461B-957F-F7BC974D2B10

Q28740430-634B9884-A296-4212-95CD-AF2D38F8FC14

Q28740430-B714A279-A28F-4C8B-B875-C90BB098F1E2

Q28740430-B8F1EEEC-26AD-4ABF-84A4-7096B8F6CF1B

Q28740430-C1FA521F-0FB7-4065-A586-0E05FA62D6A4

Q28740430-C6908ED0-6BD8-4F36-AA9E-5E5835722159

Q28740430-CA7A426E-8A93-434D-AFAA-E9BA8D701283

P2860

Q28740430-1992962D-C697-4422-A0C4-8B297A796A83

Q28740430-3911F620-6DC4-4FC2-8D81-23A9678C4DFA

Q28740430-405419FE-ACCA-43CD-97A2-B67A87973835

Q28740430-40E93A4E-8C36-4BE9-8C94-5A58D69A9895

Q28740430-4BDA242A-CDFD-4353-9146-7E143F86CFC0

Q28740430-503CCCA4-AE22-4362-A960-09BADF682B41

Q28740430-58BB9524-9DD9-47A0-8B47-64ED62F5223E

Q28740430-5A781F63-C557-43B3-BFFE-8E49AAA37233

Q28740430-5C4CFAD5-6C12-42E3-87E7-012C8E4544AB

Q28740430-5D4EA0F0-BC35-4FF9-A127-C23B224808C0

P304

Q28740430-E8810268-A4B3-48D6-B0D6-1FB48BE90070

P31

Q28740430-B8BD3F65-64BF-4CCA-A42D-02551517BB65

P356

Q28740430-D9D96EC2-D214-45E7-8E70-F8067CF2B86C

P407

Q28740430-68BF1921-D10F-400C-99E5-844C75B02A76

P433

Q28740430-7811A355-C9A9-424C-8943-D18BC3001C5A

P478

Q28740430-12EAFDF8-8808-424E-8292-6C9DC12D8A3F

P50

Q28740430-30C97E09-9691-4B94-97EC-11DB9D1C3C4B

Q28740430-77729777-D999-4097-8B2E-A0911EC92FFA

Q28740430-7916E58B-4C68-4466-9342-DF725E75253D

Q28740430-877AC0A7-7524-47A2-924C-D9F20C874C97

Q28740430-AF6F356B-6206-4DF9-823E-FCE16D3EA649

Q28740430-CB527144-3FB2-430B-A59D-5DDBA705CAAB

P577

Q28740430-743C4501-194A-4352-A3AF-0680B441CAA0

P5875

Q28740430-244CBE6A-3BD4-4E7D-A9EE-F079FEDEB90A

P698

Q28740430-BA13BF97-636C-4D28-B3FC-7B09E6885AD0

P932

Q28740430-4E8F2169-FFB7-4128-A3F6-0A7014479B57

P356

JOURNAL.PONE.0019601

P1433

P1476

Benchmarking of mutation diagnostics in clinical lung cancer specimens

@en

P2093

Beate Saal

http://www.w3.org/2001/XMLSchema#string

Bernd Timmermann

http://www.w3.org/2001/XMLSchema#string

Erich Stoelben

http://www.w3.org/2001/XMLSchema#string

Eva Markert

http://www.w3.org/2001/XMLSchema#string

Franziska Gabler

http://www.w3.org/2001/XMLSchema#string

Jürgen Wolf

http://www.w3.org/2001/XMLSchema#string

Karen Ernestus

http://www.w3.org/2001/XMLSchema#string

Kathryn Stemshorn

http://www.w3.org/2001/XMLSchema#string

Roman K Thomas

http://www.w3.org/2001/XMLSchema#string

Sascha Ansén

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

A sequencing method based on real-time pyrophosphate

Fast and accurate long-read alignment with Burrows-Wheeler transform

P304

e19601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0019601

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Peter Nürnberg

Janine Altmüller

Matthias Scheffler

Elisabeth Brambilla

P577

2011-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51127664

http://www.w3.org/2001/XMLSchema#string

P698

21573178

http://www.w3.org/2001/XMLSchema#string

P932

3088700

http://www.w3.org/2001/XMLSchema#string